Trial design: 751 adults with obesity (BMI 30, or 27 with at least one comorbidity) No type 2 diabetes 72-week follow-up Tirzepatide 10mg or 15mg vs Semaglutide 2.4mg Results at 72 weeks: When looking at tirzepatide weight loss results from SURMOUNT-5 alongside semaglutide weight loss results from the STEP trials, the gap is consistent and statistically significant across every subgroup sex, age, baseline BMI, and presence of metabolic comorbidities
Improved Cognitive Function and Mood B12 is essential for maintaining healthy nerve cells and producing neurotransmitters that regulate mood
Key Players of the GLP-1 Companion Products Market Nestle Health Science Herbalife Abbott Laboratories Conagra Brands Huel Glanbia Nutritionals Orgain Thorne HealthTech FrieslandCampina Ingredients Arla Foods Ingrdients Specialty Enzymes & Probiotics Recent Industry Developments Arla Foods Ingredients targets GLP-1 companion nutrition at Vitafoods Europe (2026), Arla Foods Ingredients has developed new solutions to meet the needs of users of GLP-1 anti-obesity medications
Patients who experienced adverse events associated with GLP-1 analogues and who did not tolerate maintenance doses of both drugs were not included in the study group
PFKFB3 lo RA T cells shift glucose toward the PPP ( By sustaining chronic upregulation of HIF-1, synovial hypoxia provides a feed-forward mechanism amplifying synovitis
This article provides a clear and comprehensive overview of the three major Semaglutide brands, their uses in Thailand, how they differ, and what patients should expect when considering each option